Deepak L. Bhatt
American cardiologist
Deepak L. Bhatt is an American interventional cardiologist, researcher, and educator. He is known for novel clinical trials in cardiovascular prevention, intervention, and heart failure.2
From Wikipedia’s article on Deepak L. Bhatt (this version), CC BY-SA 4.0.
Born 2000.1
About
He is the director of Mount Sinai Fuster Heart Hospital in New York City, the Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, and Dean for Clinical Research–Industry Partnerships. Prior, he served as the executive director of Interventional Cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and a professor of medicine at Harvard Medical School. He was given the American College of Cardiology's Distinguished Mentor Award in 2018, and in 2019, the American Heart Association (AHA) presented him with its Distinguished Scientist award, and as of 2025 he is president of the AHA New York City Board. As of 2025, Google Scholar reports that he has been cited 300,459 times, has an h-index of 216, and an i10-index of 1305.
From Wikipedia’s article on Deepak L. Bhatt, shared under CC BY-SA 4.0.2
Companies
- Bristol-Myers SquibbBoard member Jun 14, 2022 to now12
Early life and education
- 1979 to 1985Boston Latin School3
- 1985 to 1989Massachusetts Institute of Technology Bachelor of Science3
- 1989 to 1993Weill Cornell Medicine doctorate3
- 2007Harvard Medical School3
- 2007 to 2008Harvard T.H. Chan School of Public Health3
- 2011 to 2012Harvard Business School3
Bhatt graduated Boston Latin School, earned his science degree as a National Merit Scholar from MIT, an MD from Cornell and an MPH from Harvard. He received his Executive MBA from the University of Oxford in 2024.
He trained in internal medicine and cardiology at the University of Pennsylvania and Cleveland Clinic, completing fellowships in interventional cardiology and cerebral and peripheral vascular intervention. He served as chief interventional fellow at Cleveland Clinic where he worked as an interventional cardiologist, associate professor of medicine, director of the interventional cardiology fellowship, associate director of the cardiovascular medicine fellowship, and associate director of the cardiovascular coordinating center.
Later, he became Chief of Cardiology at the VA Boston Healthcare System and later served as executive director of the Interventional Cardiovascular Programs at Brigham and Women's Hospital. Additionally, he was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. In 2012, he was appointed a professor of medicine at Harvard Medical School.
Bhatt later joined the Mount Sinai Health System, where he became director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai. In 2026, he was appointed Dean for Clinical Research–Industry Partnerships at Icahn.
Read more
Board positions
As of 2024, Bhatt serves on the Board of Directors and Science and Technology Committee of Bristol Myers Squibb. He is on the cardiovascular advisory board for McKinsey and is a consultant to Broadview Ventures. He had previously served on the Board of Directors of the Boston VA Research Institute and as a Trustee of the American College of Cardiology. He is President of the Board of Directors of the American Heart Association New York City chapter.
From Wikipedia’s article on Deepak L. Bhatt (this version), CC BY-SA 4.0.
Career
Occupation: researcher, cardiologist, physician, university teacher.9
- Since 2022Worked at Icahn School of Medicine at Mount Sinai4 7
- Since 2022Board member, Bristol-Myers Squibb8
- 2008 to 2013Worked at VA Boston Healthcare System4 6
- 2001 to 2008Worked at Cleveland Clinic4 5
- Date not recordedWorked at Harvard Medical School4
Legal issues and controversies
Clinical trials
Bhatt has served as principal investigator, co-principal investigator, or steering-committee chair for multiple large, multicenter randomized controlled trials examining strategies to reduce cardiovascular events in high-risk patients. His work has included studies of sodium–glucose cotransporter2 (SGLT2) based therapies in patients with diabetes and either heart failure or chronic kidney disease, high-dose eicosapentaenoic acid (icosapent ethyl) in statin-treated patients with elevated triglycerides, intravenous antiplatelet therapy during percutaneous coronary intervention, and intensified oral antiplatelet regimens in patients with stable coronary artery disease and diabetes.
His publication record includes work on standardized bleeding definitions for cardiovascular trials, stroke and acute coronary syndrome guidelines, and large outcome studies in diabetes and chronic kidney disease, many of which are highly cited and have been referenced in clinical practice discussions and educational materials in cardiology and stroke medicine.
Selected trials
Recent trials as of 2025 include:
From Wikipedia’s article on Deepak L. Bhatt (this version), CC BY-SA 4.0.
Links
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataDeepak L. Bhatt on Wikidata
- 2WikipediaDeepak L. Bhatt on Wikipedia
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12Wikidata and SEC EDGARBristol-Myers Squibb, Board member